Onconova Therapeutics, Inc. Form 3 May 16, 2014 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number:

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol Onconova Therapeutics, Inc. [ONTX]				
05/09/2014	Person(s) to Issuer		5. If Amendment, Date Original Filed(Month/Day/Year)		
	Director X Officer (give title below) (spec	_ 10% Owner _ Other cify below)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting		
			Person Form filed by More than One Reporting Person		
Table I - I	Non-Derivative Se	curities Be	eneficially Owned		
	Owned Owner Form: Direct or Ind (I)	rship Own (Instr (D) irect	tture of Indirect Beneficial ership r. 5)		
600	Ι	DÂ			
each class of securities benefic	ially SEC 147	3 (7-02)			
tained in this form are no ond unless the form disp	t				
	Statement (Month/Day/Year) 05/09/2014 Table I - N 2. Amount on Beneficially (Instr. 4) 600 each class of securities benefic spond to the collection of tained in this form are not	Statement (Month/Day/Year) Onconova Therag 05/09/2014 4. Relationship of Re Person(s) to Issuer (Check all app)	Statement (Month/Day/Year) Onconova Therapeutics, Inc 05/09/2014 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)		

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	
			Derivative	Security:	

OMB APPROVAL

Estimated average burden hours per

Expires:

response...

3235-0104

January 31,

2005

0.5

Edgar Filing: Onconova Therapeutics, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	(1)	10/04/2023	Common Stock	30,000	\$ 28.81	D	Â
Stock Option (right to buy)	(2)	12/20/2023	Common Stock	6,000	\$ 13.48	D	Â
Stock Option (right to buy)	(2)	03/31/2024	Common Stock	24,500	\$ 6.3	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Guerin Mark Patrick C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN NEWTOWN, PA 18940	Â	Â	Chief Accounting Officer	Â	
Signatures					
N 1 G : 05/16/0014					

Mark Guerin 05/16/2014 <u>**</u>Signature of Date Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option, representing a right to purchase, vests over 4 years, with 25% vesting on October 4, 2014 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the issuer.
- (2) This option, representing a right to purchase, vests over 4 years in 48 equal monthly installments, subject to continued service to the issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.